Quick Answer
Larimar Therapeutics, Inc. reported Stockholders Equity of $78.08 million for fiscal year 2025.
Larimar Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $78.08M | -54.6% |
| 2024 | $171.81M | +110.2% |
| 2023 | $81.72M | -26.3% |
| 2022 | $110.90M | +72.2% |
| 2021 | $64.41M | -28.2% |
| 2020 | $89.69M | +13023.9% |
| 2019 | -$694.0K | -123.8% |
| 2018 | $2.91M | -96.3% |
| 2017 | $78.22M | -35.7% |
| 2016 | $121.73M | -28.0% |
| 2015 | $169.11M | +61.9% |
| 2014 | $104.44M | +252.3% |
| 2013 | -$68.57M | -25.3% |
| 2012 | -$54.73M | -33.8% |
| 2011 | -$40.92M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $139.04M | -29.9% | +16.0% |
| June 30, 2025 | $119.85M | -43.3% | -16.9% |
| March 31, 2025 | $144.27M | -37.5% | -16.0% |
| December 31, 2024 | $171.81M | +110.2% | -13.4% |
| September 30, 2024 | $198.40M | +114.0% | -6.2% |
| June 30, 2024 | $211.40M | +111.6% | -8.4% |
| March 31, 2024 | $230.84M | +117.3% | +182.5% |
| December 31, 2023 | $81.72M | -26.3% | -11.9% |
- Larimar Therapeutics, Inc. showed a decrease of -54.6% in Stockholders Equity compared to the prior fiscal year.
- Over the 2011–2025 period, Larimar Therapeutics, Inc.’s stockholders equity has grown by 290.8% (from -$40.92 million to $78.08 million).
- The most recent figure is from Larimar Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: